Publicacións nas que colabora con Laura San Segundo Payo (14)

2021

  1. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma

    Cells, Vol. 10, Núm. 3

2020

  1. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

    Haematologica

  2. Protein translation inhibition is involved in the activity of the pan-pim kinase inhibitor pim447 in combination with pomalidomide-dexamethasone in multiple myeloma

    Cancers, Vol. 12, Núm. 10, pp. 1-20

2017

  1. Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma

    Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615

  2. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  3. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone

    Haematologica, Vol. 102, Núm. 1, pp. 168-175

  4. The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

    Haematologica, Vol. 102, Núm. 12, pp. 2113-2124

  5. The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care

    Clinical Cancer Research, Vol. 23, Núm. 1, pp. 225-238

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

  2. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

2014

  1. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

    Blood, Vol. 122, Núm. 22, pp. 3591-3598

2012

  1. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

    Haematologica, Vol. 97, Núm. 7, pp. 1110-1114

  2. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma

    Annals of Hematology, Vol. 91, Núm. 2, pp. 257-269